{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:53:16Z","timestamp":1790981596286,"version":"4.1.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    A 76-year-old man with mildly elevated prostate-specific antigen (PSA, 5.44ng\/mL) and a PI-RADS 5 lesion on multiparametric MRI underwent dual-tracer PET\/CT.\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT revealed focal intense uptake in one prostatic lobe, while\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT demonstrated avid uptake in the contralateral lobe. Histopathology confirmed synchronous high-grade prostatic adenocarcinoma (Gleason 9) and sarcomatoid carcinoma with osteosarcomatous differentiation. This discordant dual-tracer pattern highlights the complementary role of PSMA and FDG PET\/CT in detecting molecularly divergent synchronous prostatic malignancies.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006576","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:48Z","timestamp":1781647308000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Divergent PET Tracer Avidity in Synchronous Sarcomatoid Carcinoma With Osteosarcomatous Differentiation and Adenocarcinoma of the Prostate"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4694-5850","authenticated-orcid":false,"given":"Efrah Ahmed","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eray","family":"Alper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"105988","DOI":"10.1016\/j.humpath.2025.105988","article-title":"Sarcomatoid carcinoma of the prostate\u2014a single institution experience with emphasis on molecular genetic findings","volume":"167","author":"Tekin","year":"2026","journal-title":"Hum Pathol"},{"key":"R2-20261002","doi-asserted-by":"crossref","first-page":"1583504","DOI":"10.3389\/fonc.2025.1583504","article-title":"Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma","volume":"15","author":"Zhuang","year":"2025","journal-title":"Front Oncol"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"R4-20261002","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00259-025-07078-5","article-title":"Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [68Ga]Ga-PSMA-11 and [\u00b9\u2078F]PSMA-1007","volume":"52","author":"Waibel","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","article-title":"Role of FDG PET\/CT in management of patients with prostate cancer","volume":"54","author":"Sutherland","year":"2024","journal-title":"Semin Nucl Med"},{"key":"R6-20261002","doi-asserted-by":"crossref","first-page":"e233337","DOI":"10.1148\/radiol.233337","article-title":"Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis","volume":"312","author":"Oerther","year":"2024","journal-title":"Radiology"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"1607227","DOI":"10.3389\/fmed.2025.1607227","article-title":"Diagnostic value of dual-tracer PET\/CT with [\u00b9\u2078F]FDG and PSMA ligands in prostate cancer: an updated systematic review","volume":"12","author":"Iacovitti","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:00:10Z","timestamp":1790978410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006576"}},"subtitle":["Insights From Dual-Tracer 68Ga-PSMA and 18F-FDG PET\/CT Imaging"],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":8,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006576","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}